Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

被引：0

作者：

Janjigian, Yelena Y. ^{[1
]}

Al-Batran, Salah-Eddin ^{[2
]}

Wainberg, Zen A. ^{[3
]}

Van Cutsem, Eric ^{[4
,5
]}

Molena, Daniela ^{[6
]}

Muro, Kei ^{[7
]}

Hyung, Woo Jin ^{[8
]}

Wyrwicz, Lucjan ^{[9
]}

Oh, Do-Youn ^{[10
,11
]}

Omori, Takeshi ^{[12
]}

Moehler, Markus ^{[13
]}

Garrido, Marcelo ^{[14
,15
]}

Oliveira, Sulene C. S. ^{[16
]}

Liberman, Moishe ^{[17
]}

Oliden, Victor C. ^{[18
]}

Bilici, Mehmet ^{[19
]}

Kurland, John ^{[20
]}

Xynos, Ioannis ^{[20
]}

Mann, Helan ^{[20
]}

Tabernero, Josep ^{[21
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA

[2] Krankenhaus NW Frankfurt, Inst Clin Canc Res, Univ Canc Ctr, Frankfurt, Germany

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gastrointestinal Med Oncol, Los Angeles, CA USA

[4] Univ Hosp Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium

[5] Katholieke Univ Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, Div Thorac Surg, New York, NY USA

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan

[13] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy FZI, Mainz, Germany

[14] Clin Trial Ctr, London, England

[15] Univ Mayor, Santiago, Chile

[16] Clin Res Ctr, Northern Riograndense League Canc, Clin Oncol, Rio De Janeiro, Brazil

[17] Ctr Rech CHUM, Ctr Hosp Univ Montreal, Div Thorac Surg, Dept Surg, Montreal, PQ, Canada

[18] Natl Inst Neoplast Dis INEN & Detecta Clin, Lima, Peru

[19] Ataturk Univ, Fac Med, Dept Med Oncol, Erzurum, Turkiye

[20] AstraZeneca, Cambridge, England

[21] UVic UCC, Vall Hebron Hosp Campus & Inst Oncol VHIO, Med Oncol Dept, IOB Quiron, Barcelona, Spain

来源：

ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S44 / S45

页数：2

共 50 条

[21] Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
Mansoor, Wasat
Arkenau, Hendrik-Tobias
Alsina, Maria
Shitara, Kohei
Thuss-Patience, Peter
Cuffe, Sinead
Dvorkin, Mikhail
Park, David
Ando, Takayuki
Van den Eynde, Marc
Beretta, Giordano D.
Zaniboni, Alberto
Doi, Toshihiko
Tabernero, Josep
Ilson, David H.
Makris, Lukas
Benhadji, Karim A.
Van Cutsem, Eric
GASTRIC CANCER, 2021, 24 (04) : 970 - 977
[22] Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a randomized, multicenter phase 3 trial
Al-Batran, S. -E.
Pauligk, C.
Homann, N.
Schmalenberg, H.
Kopp, H. -G.
Haag, G. M.
Luley, K. B.
Schmiegel, W.
Folprecht, G.
Probst, S.
Prasnikar, N.
Thuss-Patience, P.
Fischbach, W.
Trojan, J.
Koenigsmann, M.
Goetze, T. O.
Kraus, T. W.
Battmann, A.
Moenig, S. P.
Bechstein, W.
Gaiser, T.
Tannapfel, A.
Jaeger, E.
Schuler, M.
Lindig, U.
Pohl, M.
Kasper, S.
Moehler, M.
Hofheinz, R. D.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 200 - +
[23] A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376).
Cohen, D. J.
Liebes, L.
Xu, R.
Takebe, N.
Sparano, J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[24] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study
Chung, Hyun Cheol
Bang, Yung-Jue
Fuchs, Charles S.
Qin, Shukui
Satoh, Taroh
Shitara, Kohei
Tabernero, Josep
Van Cutsem, Eric
Alsina, Maria
Cao, Z. Alexander
Chen, Xinqun
Bhagia, Pooja
Shih, Chie-Schin
Janjigian, Yelena Yuriy
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[25] Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.
Al-Batran, Salah-Eddin
Shitara, Kohei
Folprecht, Gunnar
Moehler, Markus H.
Goekkurt, Eray
Ben-Aharon, Irit
Lonardi, Sara
Stein, Stacey
Hubert, Ayala
Chau, Ian
Mishaeli, Moshe
Villanueva, Luis
Kavan, Petr
Fang, Xiao
Shih, Chie-Schin
Bhagia, Pooja
Wyrwicz, Lucjan S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 247 - 247
[26] Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
Al-Batran, Salah-Eddin
Homann, Nils
Schmalenberg, Harald
Knopp, Hans-Georg
Georg
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Tabernero, J.
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Janjigian, Y.
Bhagia, P.
Li, K.
Adelberg, D.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
[28] CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.
Kelly, Ronan Joseph
Lockhart, Albert C.
Jonker, Derek J.
Melichar, Bohuslav
Andre, Thierry
Chau, Ian
Clarke, Stephen John
Cleary, James M.
Doki, Yuichiro
Franke, Fabio A.
Kitagawa, Yuko
Marlette, Christophe
Montenegro, Paola Catherine
Mendez, Guillermo Ariel
Ciprotti, Marika
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study
Ogata, Takatsugu
Narita, Yukiya
Wainberg, Zev A.
Van Cutsem, Eric
Yamaguchi, Kensei
Piao, Yongzhe
Zhao, Yumin
Peterson, Patrick M.
Wijayawardana, Sameera R.
Abada, Paolo
Chatterjee, Anindya
Muro, Kei
JOURNAL OF GASTRIC CANCER, 2023, 23 (02) : 289 - 302
[30] CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.
Kelly, Ronan Joseph
Lockhart, Albert C.
Jonker, Derek J.
Melichar, Bohuslav
Andre, Thierry
Chau, Ian
Clarke, Stephen John
Cleary, James M.
Doki, Yuichiro
Franke, Fabio Andre
Kitagawa, Yuko
Mariette, Christophe
Montenegro, Paola Catherine
Roca, Enrique Luis
Ciprotti, Marika
Moehler, Markus
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 2 3 4 5 →